

~~10/256,198~~

=> d his

(FILE 'HOME' ENTERED AT 11:44:57 ON 27 SEP 2005)

FILE 'REGISTRY' ENTERED AT 11:45:03 ON 27 SEP 2005

L1                   STRUCTURE UPLOADED

L2                   14 S L1

L3                   275 S L1 SSS FUL

FILE 'CAPLUS' ENTERED AT 11:46:52 ON 27 SEP 2005

L4                   9 S L3

=> d ibib abs hitstr total

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:546469 CAPLUS

DOCUMENT NUMBER: 141:106266

TITLE: Preparation of phenylpropanoic acids derivatives as selective PPAR $\alpha$  modulatorsINVENTOR(S): Lindstedt Alstermark, Eva-Lotte; Olsson, Anna  
Christina; Li, Lanna; Aurell, Carl-Johan; Minidis,  
Anna; Yousefi-Salakdeh, Esmail; Dahlstrom, Mikael Ulf  
Johan

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 43 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004056748	A1	20040708	WO 2003-GB5602	20031219
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2508851	AA	20040708	CA 2003-2508851	20031219
US 2005131068	A1	20050616	US 2003-499893	20031219
EP 1572626	A1	20050914	EP 2003-782668	20031219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.:			GB 2002-29931	A 20021221
			WO 2003-GB5602	W 20031219
OTHER SOURCE(S):			CASREACT 141:106266; MARPAT 141:106266	
GI				



AB Title compds. I [R1 = Cl, CF3, CF3O; R2 = H, F; R3 = alkyl] and their pharmaceutically acceptable salts, prodrugs were prepared For example, amidation of N-butyl-N-[2-fluoro-4-(trifluoromethyl)benzyl]amine, e.g., prepared from Et (2S)-2-ethoxy-3-(4-hydroxyphenyl)propanoate in 3 steps, and {4-[(2S)-2,3-diethoxy-3-oxopropyl]phenoxy}acetic acid, followed by

hydrolysis afforded compound (S)-I [R1 = CF3; R2 = F; R3 = butyl] in 72% yield. Compds. I have EC50 values <0.1  $\mu\text{mol/L}$  for PPAR $\alpha$ , e.g., the EC50 value of compound (S)-I [R1 = CF3; R2 = F; R3 = butyl] was 0.001  $\mu\text{mol/L}$ . Of notes, compds. I exhibit improved metabolic stability (in vitro), promising toxicol. profile (no data provided) and particular compds. have the ratio of the EC50(PPAR $\gamma$ ):EC50(PPAR $\alpha$ ) <150:1. Compds. I are claimed useful for the treatment of hypertension, diabetes, etc.


IT 439087-18-0 439087-21-5 439087-31-7  
 439087-34-0 439087-36-2 439087-37-3  
 439087-38-4 439087-48-6 439087-61-3  
 439087-63-5 439087-77-1 439087-88-4  
 439087-89-5 439087-96-4 439088-00-3  
 439088-01-4 439088-02-5 439088-03-6  
 549501-76-0 549501-77-1 549501-79-3  
 549501-80-6

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (medicaments with; preparation of phenylpropanoic acids derivs. as selective PPAR $\alpha$  modulators for treatment of dyslipidemia)

RN 439087-18-0 CAPLUS

CN Glycine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI)  
 (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-21-5 CAPLUS

CN Glycine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/256,198

RN 439087-31-7 CAPLUS

CN Ethanesulfonic acid, 2-[[[(2R)-[[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino](4-hydroxyphenyl)acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-34-0 CAPLUS

CN  $\beta$ -Alanine, (2R)-N-[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-36-2 CAPLUS

CN  $\beta$ -Alanine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 439087-37-3 CAPLUS

CN Hexanoic acid, 6-[[[(2R)-[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-38-4 CAPLUS


CN  $\beta$ -Alanine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439087-48-6 CAPLUS

CN Ethanesulfonic acid, 2-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino] (2-fluorophenyl)acetyl]amino]- (9CI) (CA INDEX NAME)




RN 439087-61-3 CAPLUS

CN D-Serine, (2R)-N-[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-

dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 439087-63-5 CAPLUS

CN D-Serine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 439087-77-1 CAPLUS

CN Phosphinic acid, [2-[[ (2R)-[[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]ethyl]methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439087-88-4 CAPLUS

CN Benzeneacetamide, α-[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-

(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-N-[2-(ethylmethylphosphinyl)ethyl]-4-hydroxy-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-89-5 CAPLUS

CN Phosphinic acid, [2-[[[(2R)-[[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino] (4-hydroxyphenyl)acetyl]amino]ethyl]methyl- (9CI) (CA INDEX NAME)]


Absolute stereochemistry.



RN 439087-96-4 CAPLUS

CN Ethanesulfonic acid, 2-[[[(2R)-[[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-methoxy-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino] (4-hydroxyphenyl)acetyl]amino]- (9CI) (CA INDEX NAME)]


Absolute stereochemistry.



RN 439088-00-3 CAPLUS

CN Ethanesulfonic acid, 2-[[[(2R)-[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439088-01-4 CAPLUS

CN Ethanesulfonic acid, 2-[[[(2R)-[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino] (4-hydroxyphenyl)acetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439088-02-5 CAPLUS

CN D-Serine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-D-seryl- (9CI) (CA INDEX NAME)


10/256,198

Absolute stereochemistry.



RN 439088-03-6 CAPLUS


CN Phosphinic acid, [[[[[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]methyl]methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 549501-76-0 CAPLUS


CN Ethanesulfonic acid, 2-[[[(2R)-[[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 549501-77-1 CAPLUS


CN Glycine, N-[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI) (CA INDEX NAME)



RN 549501-79-3 CAPLUS

CN Cysteine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-S-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 549501-80-6 CAPLUS

CN L-Alanine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-3-(methylsulfinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:60291 CAPLUS

DOCUMENT NUMBER: 140:117399

TITLE: Combination of an ileal bile acid transport inhibitor and a metal salt for the treatment of diarrhea

INVENTOR(S): Anderberg, Eva-Karin; Soederlind, Erik

PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 71 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004006899	A1	20040122	WO 2003-GB2978	20030709
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2492374	AA	20040122	CA 2003-2492374	20030709
BR 2003012427	A	20050419	BR 2003-12427	20030709
EP 1539120	A1	20050615	EP 2003-763979	20030709
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
PRIORITY APPLN. INFO.:			GB 2002-16321	A 20020713
			WO 2003-GB2978	W 20030709

AB A combination comprising an IBAT inhibitor, or a pharmaceutically acceptable salt, solvate of such a salt or a prodrug thereof, and a metal salt, wherein the metal salt is formulated to release in the terminal ileum, cecum and/or the colon, is described. Comps. containing this combination and uses of the combination are also described.

IT 439086-77-8 439087-18-0 439087-21-5  
 439087-27-1 439087-31-7 439087-34-0  
 439087-36-2 439087-37-3 439087-38-4  
 439087-60-2 439087-63-5 439087-74-8  
 439087-77-1 439087-83-9 439087-87-3  
 439087-89-5 439087-96-4 439088-00-3  
 439088-01-4 439088-02-5 549501-76-0  
 549501-80-6 549532-37-8 636565-35-0  
 636565-36-1 636565-39-4 636565-41-8  
 636565-44-1 636565-47-4 636565-48-5  
 636565-49-6 636565-53-2 647012-45-1  
 647012-47-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(combination of an ileal bile acid transport inhibitor and a metal salt for the treatment of diarrhea)

RN 439086-77-8 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-

yl]oxy]acetyl]amino]-4-hydroxy-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-18-0 CAPLUS

CN Glycine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-21-5 CAPLUS

CN Glycine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439087-27-1 CAPLUS

CN Glycine, (2R)-N-[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI)



(CA INDEX NAME)


Absolute stereochemistry.



RN 439087-31-7 CAPLUS

CN Ethanesulfonic acid, 2-[[[(2R)-[[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino](4-hydroxyphenyl)acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-34-0 CAPLUS

CN  $\beta$ -Alanine, (2R)-N-[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439087-36-2 CAPLUS

CN  $\beta$ -Alanine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-(4-

hydroxyphenyl)glycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-37-3 CAPLUS

CN Hexanoic acid, 6-[[[(2R)-[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-38-4 CAPLUS

CN  $\beta$ -Alanine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439087-60-2 CAPLUS

CN L-Serine, (2R)-N-[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 439087-63-5 CAPLUS

CN D-Serine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 439087-74-8 CAPLUS

CN Phosphinic acid, [2-[[[(2R)-[[[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]ethyl]methyl-, ethyl ester (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 439087-77-1 CAPLUS

CN Phosphinic acid, [2-[[[(2R)-[[[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-

yl]oxy]acetyl]amino]phenylacetyl]amino]ethyl]methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-83-9 CAPLUS

CN Benzeneacetamide,  $\alpha$ -[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-N-[2-(ethylmethylphosphinyl)ethyl]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-87-3 CAPLUS

CN L-Cysteine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-2-phenylglycyl-S-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439087-89-5 CAPLUS

CN Phosphinic acid, [2-[[[2R)-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-

(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino] (4-hydroxyphenyl)acetyl]amino]ethyl]methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-96-4 CAPLUS

CN Ethanesulfonic acid, 2-[[[(2R)-[[[(3,3-dibutyl-2,3,4,5-tetrahydro-7-methoxy-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl)oxy]acetyl]amino] (4-hydroxyphenyl)acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439088-00-3 CAPLUS

CN Ethanesulfonic acid, 2-[[[(2R)-[[[(3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl)oxy]acetyl]amino]phenylacetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439088-01-4 CAPLUS

CN Ethanesulfonic acid, 2-[[[(2R)-[[[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino](4-hydroxyphenyl)acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439088-02-5 CAPLUS

CN D-Serine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-D-seryl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 549501-76-0 CAPLUS

CN Ethanesulfonic acid, 2-[[[(2R)-[[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/256,198

RN 549501-80-6 CAPLUS

CN L-Alanine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-3-(methylsulfinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 549532-37-8 CAPLUS

CN Ethanesulfonic acid, 2-[[[(2R)-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino](2-fluorophenyl)acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 636565-35-0 CAPLUS

CN Butanoic acid, 2-[[[(2R)-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino](4-hydroxyphenyl)acetyl]amino]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 636565-36-1 CAPLUS

CN L-Alanine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 636565-39-4 CAPLUS

CN Butanoic acid, 2-[[[(2R)-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 636565-41-8 CAPLUS

CN L-Valine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI)  
(CA INDEX NAME)




Absolute stereochemistry.



RN 636565-44-1 CAPLUS

CN L-Threonine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 636565-47-4 CAPLUS

CN L-Alanine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 636565-48-5 CAPLUS

CN L-Norvaline, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-

dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 636565-49-6 CAPLUS

CN L-Valine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 636565-53-2 CAPLUS

CN L-Threonine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 647012-45-1 CAPLUS

CN L-Cysteine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl-S-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 647012-47-3 CAPLUS

CN L-Serine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-(2S)-2-aminobutanoyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/256,198

REFERENCE COUNT:

5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:1007004 CAPLUS

DOCUMENT NUMBER: 140:35962

TITLE: Peptides derivatives comprising thiazepine group for the treatment of hyperlipidemic conditions

INVENTOR(S): Starke, Ingemar; Dahlstrom, Mikael Ulf Johan; Alenfalk, Suzanne; Skjaret, Tore; Lemurell, Malin

PATENT ASSIGNEE(S): Astrazeneca A.B., Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 52 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003106482	A1	20031224	WO 2003-GB2499	20030610
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2489463	AA	20031224	CA 2003-2489463	20030610
BR 2003011628	A	20050308	BR 2003-11628	20030610
EP 1515984	A1	20050323	EP 2003-732693	20030610
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
PRIORITY APPLN. INFO.:			GB 2002-13669	A 20020614
			WO 2003-GB2499	W 20030610
OTHER SOURCE(S):	MARPAT 140:35962			
GI				



I

AB The present invention relates to compds. of formula I (R1 and R2 are independently selected from C1-4alkyl; R3 is hydrogen, hydroxy or halo; R4 is C1-4alkyl optionally substituted by hydroxy, methoxy and methylS(O)a wherein a is 0-2; R5 is hydroxy or HOC(O)CH(R6)NHI-; and R6 is selected from hydrogen and C1-3alkyl optionally substituted by hydroxy, methoxy and methylS(O)a wherein a is 0-2), pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidemia. Processes for their manufacture and pharmaceutical compns. containing them are also described. The compds. of the invention may be administered together with HMGCoA reductase inhibitors of PPAR $\alpha$  or PPAR $\gamma$  agonists.

IT **636565-35-0P**


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(peptides derivs. comprising thiazepine group for treatment of hyperlipidemic conditions by inhibiting ileal bile acid transport and their combination with other agents)

RN 636565-35-0 CAPLUS

CN Butanoic acid, 2-[[[(2R)-[[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino](4-hydroxyphenyl)acetyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **636565-39-4 636565-40-7 636565-41-8**  
**636565-42-9 636565-43-0 636565-44-1**  
**636565-45-2 636565-46-3 636565-47-4**  
**636565-48-5 636565-49-6 636565-50-9**  
**636565-51-0 636565-52-1 636565-53-2**  
**636565-54-3 636565-55-4 636565-56-5**  
**636565-57-6 636565-58-7 636565-59-8**  
**636565-60-1**

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(peptides derivs. comprising thiazepine group for treatment of hyperlipidemic conditions by inhibiting ileal bile acid transport and their combination with other agents)

RN 636565-39-4 CAPLUS

CN Butanoic acid, 2-[[[(2R)-[[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]

]amino]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 636565-40-7 CAPLUS

CN L-Norvaline, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 636565-41-8 CAPLUS

CN L-Valine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 636565-42-9 CAPLUS

CN L-Isoleucine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 636565-43-0 CAPLUS

CN L-Leucine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 636565-44-1 CAPLUS

CN L-Threonine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 636565-45-2 CAPLUS

CN L-Alanine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-3-(methylsulfonyl)- (9CI) (CA INDEX NAME)




Absolute stereochemistry.



RN 636565-46-3 CAPLUS

CN Butanoic acid, 2-[[[(2R)-[[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]-4-(methylsulfonyl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 636565-47-4 CAPLUS

CN L-Alanine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 636565-48-5 CAPLUS

CN L-Norvaline, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-(4-

hydroxyphenyl)glycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 636565-49-6 CAPLUS

CN L-Valine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry:



RN 636565-50-9 CAPLUS

CN L-Isoleucine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 636565-51-0 CAPLUS

CN L-Leucine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 636565-52-1 CAPLUS

CN L-Serine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 636565-53-2 CAPLUS

CN L-Threonine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 636565-54-3 CAPLUS

CN D-Cysteine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl-S-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 636565-55-4 CAPLUS

CN D-Alanine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl-3-(methylsulfinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 636565-56-5 CAPLUS

CN D-Alanine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl-3-(methylsulfonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 636565-57-6 CAPLUS

CN L-Serine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 636565-58-7 CAPLUS

CN L-Methionine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 636565-59-8 CAPLUS

CN Butanoic acid, 2-[[[(2R)-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino](4-hydroxyphenyl)acetyl]amino]-4-(methylsulfinyl)-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 636565-60-1 CAPLUS

CN Butanoic acid, 2-[[[(2R)-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino](4-hydroxyphenyl)acetyl]amino]-4-(methylsulfonyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 439086-76-7 439086-77-8


RL: RCT (Reactant); RACT (Reactant or reagent)

(peptides derivs. comprising thiazepine group for treatment of hyperlipidemic conditions by inhibiting ileal bile acid transport and their combination with other agents)

RN 439086-76-7 CAPLUS

CN Benzeneacetic acid, α-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439086-77-8 CAPLUS

CN Benzeneacetic acid, α-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-4-hydroxy-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





IT 439088-19-4P 636565-36-1P 636565-37-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(peptides derivs. comprising thiazepine group for treatment of hyperlipidemic conditions by inhibiting ileal bile acid transport and their combination with other agents)

RN 439088-19-4 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-, methyl ester, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 636565-36-1 CAPLUS

CN L-Alanine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 636565-37-2 CAPLUS

10/256,198

CN L-Alanine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:591008 CAPLUS

DOCUMENT NUMBER: 139:128038

TITLE: Use of benzothiazepines having activity as inhibitors of ileal bile acid transport for reducing hypercholesterolemia

INVENTOR(S): Lindqvist, Ann-Margret

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 56 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003061663	A1	20030731	WO 2003-GB350	20030123
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2473721	AA	20030731	CA 2003-2473721	20030123
EP 1478368	A1	20041124	EP 2003-731763	20030123
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2003007093	A	20041228	BR 2003-7093	20030123
US 2005124557	A1	20050609	US 2003-502355	20030123
JP 2005523255	T2	20050804	JP 2003-561607	20030123
PRIORITY APPLN. INFO.:			GB 2002-1850	A 20020126
			WO 2003-GB350	W 20030123

OTHER SOURCE(S): MARPAT 139:128038

AB The invention describes the use of an ileal bile acid transport (IBAT) inhibitor and the use of a combination of an IBAT inhibitor and an HMG-CoA reductase inhibitor in the treatment of a warm-blooded animal, such as man, with hypercholesterolemia and/or other forms of dyslipidemia wherein the hypercholesterolemia and dyslipidemias are characterized by defects in lipoproteins or their receptors.

IT 439087-18-0 439087-21-5 439087-31-7  
 439087-34-0 439087-36-2 439087-37-3  
 439087-38-4 439087-48-6 439087-61-3  
 439087-63-5 439087-77-1 439087-88-4  
 439087-89-5 439087-96-4 439088-00-3  
 439088-01-4 439088-02-5 439088-03-6  
 549501-76-0 549501-77-1 549501-79-3  
 549501-80-6


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(benzothiazepines ileal bile acid transport inhibitors for treatment of hypercholesterolemia and dyslipidemia, and use with HMG-CoA reductase inhibitors)

RN 439087-18-0 CAPLUS

CN Glycine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 439087-21-5 CAPLUS

CN Glycine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-31-7 CAPLUS

CN Ethanesulfonic acid, 2-[[[(2R)-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino](4-hydroxyphenyl)acetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/256,198

RN 439087-34-0 CAPLUS

CN  $\beta$ -Alanine, (2R)-N-[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-36-2 CAPLUS

CN  $\beta$ -Alanine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-37-3 CAPLUS

CN Hexanoic acid, 6-[[[(2R)-[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-38-4 CAPLUS


CN  $\beta$ -Alanine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439087-48-6 CAPLUS


CN Ethanesulfonic acid, 2-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino] (2-fluorophenyl)acetyl]amino]- (9CI) (CA INDEX NAME)



RN 439087-61-3 CAPLUS

CN D-Serine, (2R)-N-[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439087-63-5 CAPLUS

CN D-Serine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 439087-77-1 CAPLUS

CN Phosphinic acid, [2-[[[(2R)-[[[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]ethyl]methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-88-4 CAPLUS

CN Benzeneacetamide, α-[[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-N-[2-(ethylmethylphosphinyl)ethyl]-4-hydroxy-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-89-5 CAPLUS

CN Phosphinic acid, [2-[[[(2R)-[[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino] (4-hydroxyphenyl)acetyl]amino]ethyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-96-4 CAPLUS

CN Ethanesulfonic acid, 2-[[[(2R)-[[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-methoxy-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino] (4-hydroxyphenyl)acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439088-00-3 CAPLUS

CN Ethanesulfonic acid, 2-[[[(2R)-[[[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 439088-01-4 CAPLUS

CN Ethanesulfonic acid, 2-[[[(2R)-[[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino](4-hydroxyphenyl)acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439088-02-5 CAPLUS


CN D-Serine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-D-seryl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439088-03-6 CAPLUS


CN Phosphinic acid, [[[[[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]methyl]methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 549501-76-0 CAPLUS


CN Ethanesulfonic acid, 2-[[[(2R)-[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 549501-77-1 CAPLUS


CN Glycine, N-[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI) (CA INDEX NAME)



RN 549501-79-3 CAPLUS

CN Cysteine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-S-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 549501-80-6 CAPLUS

CN L-Alanine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-3-(methylsulfinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:491169 CAPLUS

DOCUMENT NUMBER: 139:69054

TITLE: Preparation of substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (PPAR)

INVENTOR(S): Alstermark Lindstedt, Eva-Lotte; Olsson, Anna Christina; Li, Lanna

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 43 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003051822	A1	20030626	WO 2002-GB5744	20021218
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2469302	AA	20030626	CA 2002-2469302	20021218
EP 1458672	A1	20040922	EP 2002-788145	20021218
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002014986	A	20041214	BR 2002-14986	20021218
US 2005113362	A1	20050526	US 2003-499378	20021218
JP 2005526704	T2	20050908	JP 2003-552710	20021218
PRIORITY APPLN. INFO.:			SE 2001-4334	A 20011219
			WO 2002-GB5744	W 20021218
OTHER SOURCE(S):		MARPAT 139:69054		
GI				



AB The present invention provides the S enantiomer of a compound of formula (I) (wherein R1 represents 2,4-difluorophenyl or cyclohexyl) as well as pharmaceutically acceptable salts, solvates, crystalline forms and prodrugs

thereof, processes for preparing such compds., their the utility in treating clin. conditions including lipid disorders (dyslipidemias) whether or not associated with insulin resistance, methods for their therapeutic use, and pharmaceutical compns. containing them. Thus, to a solution of [4-((2S)-2,3-diethoxy-3-oxopropyl)phenoxy]acetic acid (0.108 g) 3.6 mL CH<sub>2</sub>Cl<sub>2</sub> were added N-(cyclohexylmethyl)-N-heptylamine hydrochloride (0.090 g) and DMAP (0.098 g) followed by 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.070 g) and the reaction mixture was stirred at room temperature overnight to give, after workup and silica

gel chromatog., Et (2S)-3-[4-[2-[(cyclohexylmethyl)(heptyl)amino]-2-oxoethoxy]phenyl]-2-ethoxypropanoate which (0.031 g) was saponified with LiOH in aqueous THF at room temperature overnight and acidified with aqueous 2 M HCl to give

(2S)-3-[4-[2-[(cyclohexylmethyl)(heptyl)amino]-2-oxoethoxy]phenyl]-2-ethoxypropanoic acid. The compds. I had EC<sub>50</sub> of less than 0.5 µmol/L for PPAR $\alpha$  and preferred compds. have EC<sub>50</sub> of less than 0.05 µmol/L for PPAR $\alpha$ . They were more potent with respect to PPAR $\alpha$  than with respect to PPAR $\gamma$ .

IT 439087-18-0 439087-21-5 439087-31-7  
439087-34-0 439087-36-2 439087-37-3  
439087-38-4 439087-48-6 439087-61-3  
439087-63-5 439087-88-4 439087-89-5  
439087-96-4 439088-00-3 439088-01-4  
439088-02-5 439088-03-6 549501-76-0  
549501-77-1 549501-78-2 549501-79-3  
549501-80-6

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(ideal bile acid transport system (IBAT) inhibitor, drug containing; preparation

of substituted phenylpropionic acid derivs. as agonists to human peroxisome proliferator-activated receptor alpha (PPAR) for treating lipid disorders)

RN 439087-18-0 CAPLUS

CN Glycine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 439087-21-5 CAPLUS

CN Glycine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-31-7 CAPLUS

CN Ethanesulfonic acid, 2-[[[(2R)-[[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino](4-hydroxyphenyl)acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-34-0 CAPLUS

CN  $\beta$ -Alanine, (2R)-N-[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-36-2 CAPLUS

CN  $\beta$ -Alanine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




CN Hexanoic acid, 6-[[[(2R)-[[[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]- (9CI) (CA INDEX NAME)

CCCCCNC(=O)[C@H](c1ccccc1)NC(=O)COc2cc(Sc)c3cc4c(c2)nc(cc34S(=O)(=O)C5CCCCC5)C6=CC=CC=C6

CN     $\beta$ -Alanine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-  
(9CI)    (CA INDEX NAME)

CCCC1(C)CCN(C1C2=CC=C(C=C2)C(=O)OCCSCC3=CC=C(C=C3)C)C(=O)OCCSCC4=CC=C(C=C4)C


CN    Ethanesulfonic acid, 2-[[[[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino](2-fluorophenyl)acetyl]amino]- (9CI)    (CA INDEX NAME)



RN 439087-61-3 CAPLUS

CN D-Serine, (2R)-N-[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 439087-63-5 CAPLUS

CN D-Serine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 439087-88-4 CAPLUS

CN Benzeneacetamide, α-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-N-[2-(ethylmethylphosphinyl)ethyl]-4-hydroxy-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 439087-89-5 CAPLUS

CN Phosphinic acid, [2-[[ (2R)-[[[ (3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino] (4-hydroxyphenyl)acetyl]amino]ethyl]methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-96-4 CAPLUS

CN Ethanesulfonic acid, 2-[[ (2R)-[[[ (3,3-dibutyl-2,3,4,5-tetrahydro-7-methoxy-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino] (4-hydroxyphenyl)acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439088-00-3 CAPLUS

CN Ethanesulfonic acid, 2-[[ (2R)-[[[ (3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439088-01-4 CAPLUS

CN Ethanesulfonic acid, 2-[[[(2R)-[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-(4-hydroxyphenyl)acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439088-02-5 CAPLUS


CN D-Serine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-D-seryl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439088-03-6 CAPLUS


CN Phosphinic acid, [[[[[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]methyl]methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 549501-76-0 CAPLUS


CN Ethanesulfonic acid, 2-[[[(2R)-[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 549501-77-1 CAPLUS

CN Glycine, N-[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI) (CA INDEX NAME)



RN 549501-78-2 CAPLUS


CN Phosphinic acid, [2-[[[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]ethyl]methyl- (9CI) (CA INDEX NAME)



RN 549501-79-3 CAPLUS

CN Cysteine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-S-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 549501-80-6 CAPLUS

CN L-Alanine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-3-(methylsulfinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

8

THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:491168 CAPLUS

DOCUMENT NUMBER: 139:69049

TITLE: Preparation of substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (PPAR)

INVENTOR(S): Alstermark Lindstedt, Eva-Lotte; Olsson, Anna Christina; Li, Lanna

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 40 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003051821	A1	20030626	WO 2002-GB5738	20021218
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2470491	AA	20030626	CA 2002-2470491	20021218
EP 1458673	A1	20040922	EP 2002-804964	20021218
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002014988	A	20041214	BR 2002-14988	20021218
US 2005171204	A1	20050804	US 2003-499261	20021218
JP 2005526011	T2	20050902	JP 2003-552709	20021218
PRIORITY APPLN. INFO.:			SE 2001-4334	A 20011219
			WO 2002-GB5738	W 20021218
OTHER SOURCE(S):		MARPAT 139:69049		
GI				



AB The S enantiomer of I,  $n = 1$  or  $2$ , ( $\text{C}_6\text{H}_{13}$  = hexyl) as well as their pharmaceutically acceptable salts, solvates, crystalline forms and prodrugs are synthesized using various solvents and in presence of charcoal-supported palladium catalyst. The utility of these compds. in clin. conditions such as lipid disorders (dyslipidemias) whether or not associated with insulin resistance and therapeutic and other pharmaceutical activities is also investigated. For example, (2S)-3-(4{2-[benzyl(hexyl)amino]-2-

oxoethoxy}phenyl)2-ethoxypropionic acid was prepared in 58% yield via reaction of (2S)-2-ethoxy-3-(4-hydroxyphenyl)propanoate and benzyl bromoacetate.

IT 439087-18-0P 439087-21-5P 439087-27-1P  
 439087-31-7P 439087-34-0P 439087-36-2P  
 439087-37-3P 439087-38-4P 439087-61-3P  
 439087-63-5P 439087-74-8P 439087-77-1P  
 439087-83-9P 439087-87-3P 439087-89-5P  
 439087-96-4P 439088-00-3P 439088-01-4P  
 439088-02-5P 501098-56-2P 549501-76-0P  
 549501-80-6P 549532-37-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of enantiomeric substituted phenylpropionic acid derivs. as agonists to human peroxisome proliferator-activated receptor)

RN 439087-18-0 CAPLUS

CN Glycine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI)  
 (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-21-5 CAPLUS

CN Glycine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439087-27-1 CAPLUS

CN Glycine, (2R)-N-[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 439087-31-7 CAPLUS

CN Ethanesulfonic acid, 2-[[[(2R)-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino](4-hydroxyphenyl)acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-34-0 CAPLUS

CN  $\beta$ -Alanine, (2R)-N-[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439087-36-2 CAPLUS

CN  $\beta$ -Alanine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-(4-

hydroxyphenyl)glycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-37-3 CAPLUS

CN Hexanoic acid, 6-[[ (2R)-[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-38-4 CAPLUS

CN  $\beta$ -Alanine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439087-61-3 CAPLUS

CN D-Serine, (2R)-N-[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI)



(CA INDEX NAME)


Absolute stereochemistry.



RN 439087-63-5 CAPLUS

CN D-Serine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 439087-74-8 CAPLUS

CN Phosphinic acid, [2-[[[(2R)-[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]ethyl]methyl-, ethyl ester (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 439087-77-1 CAPLUS

CN Phosphinic acid, [2-[[[(2R)-[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-

yl]oxy]acetyl]amino]phenylacetyl]amino]ethyl]methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-83-9 CAPLUS

CN Benzeneacetamide,  $\alpha$ -[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-N-[2-(ethylmethylphosphinyl)ethyl]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-87-3 CAPLUS

CN L-Cysteine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-S-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439087-89-5 CAPLUS

CN Phosphinic acid, [2-[(2R)-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-

(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino] (4-hydroxyphenyl)acetyl]amino]ethyl]methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-96-4 CAPLUS

CN Ethanesulfonic acid, 2-[[[(2R)-[[[(3,3-dibutyl-2,3,4,5-tetrahydro-7-methoxy-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl)oxy]acetyl]amino] (4-hydroxyphenyl)acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439088-00-3 CAPLUS

CN Ethanesulfonic acid, 2-[[[(2R)-[[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439088-01-4 CAPLUS

CN Ethanesulfonic acid, 2-[[[(2R)-[[[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino](4-hydroxyphenyl)acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439088-02-5 CAPLUS

CN D-Serine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-D-seryl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 501098-56-2 CAPLUS

CN D-Glucitol, 1-deoxy-1-[[[(2R)-[[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/256,198

RN 549501-76-0 CAPLUS

CN Ethanesulfonic acid, 2-[[[(2R)-[[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 549501-80-6 CAPLUS

CN L-Alanine, (2R)-N-[[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-3-(methylsulfinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 549532-37-8 CAPLUS

CN Ethanesulfonic acid, 2-[[[(2R)-[[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino](2-fluorophenyl)acetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

8

THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:202631 CAPLUS

DOCUMENT NUMBER: 138:221607

TITLE: Preparation of benzothiazepine derivatives for potential use as ileal bile acid transport inhibitors for the treatment of hyperlipidemia

INVENTOR(S): Starke, Ingemar; Dahlstrom, Mikael Ulf Johan; Blomberg, David; Alenfalk, Suzanne; Nordberg, Peter; Wallberg, Andreas Christer; Bostrom, Stig Jonas

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 92 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003020710	A1	20030313	WO 2002-GB3983	20020830
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2459346	AA	20030313	CA 2002-2459346	20020830
EP 1430040	A1	20040623	EP 2002-755285	20020830
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002012277	A	20041019	BR 2002-12277	20020830
JP 2005505554	T2	20050224	JP 2003-524981	20020830
ZA 2004001551	A	20041124	ZA 2004-1551	20040225
NO 2004000924	A	20040421	NO 2004-924	20040303
US 2004254160	A1	20041216	US 2004-488540	20040723
PRIORITY APPLN. INFO.:			GB 2001-21337	A 20010904
			WO 2002-GB3983	W 20020830
OTHER SOURCE(S):		MARPAT 138:221607		
GI				



AB Benzothiazepines I, wherein R1 and R2 are selected from hydrogen or alkyl and the other is selected from alkyl; R3 and R6 and the other of R4 and R5 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, alkyl, alkenyl, alkynyl, alkoxy, alkanoyl, alkanoyloxy, N-(alkyl)amino, N,N-(alkyl)2amino, alkanoylamino, N-(alkyl)carbamoyl, N,N-(alkyl)2carbamoyl, alkyl-S(O)<sub>a</sub> wherein a is 0-2, alkoxycarbonyl, N-(alkyl)sulfamoyl and N,N-(alkyl)2sulfamoyl; wherein R3 and R6 and the other of R4 and R5 may be optionally substituted on carbon; R7 and R8 are independently selected from H or alkyl, or one of R7 and R8 is H or alkyl and the other is hydroxy or alkoxy; R9 and R10 are independently selected from H or alkyl; R11 is (R<sub>z</sub>)<sub>v</sub>; R<sub>z</sub> is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, alkyl, alkenyl, alkynyl, alkoxy, alkanoyl, alkanoyloxy, N-(alkyl)amino, N,N-(alkyl)2amino, alkanoylamino, N-(alkyl)carbamoyl, N,N-(alkyl)2carbamoyl, alkyl-S(O)<sub>a</sub> wherein a is 0 to 2, alkoxycarbonyl, N-(alkyl)sulfamoyl and N,N-(alkyl)2sulfamoyl; v is 0-5; variable groups are as defined within; pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidemia. Processes for their manufacture and pharmaceutical compns. containing them are also described. Thus, 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)-α-[N'-methyl-N'-(2-(S)-3-(R)-4-(R)-5-(R)-2,3,4,5,6-pentahydroxyhexyl)carbamoyl]benzyl}carbamoyl-methoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine was prepared and tested as ileal bile acid transport inhibitor and for the treatment of hyperlipidemia (no data).

IT 439086-76-7P 439086-97-2P 439087-13-5P  
439087-18-0P 439088-19-4P 439088-54-7P  
501098-36-8P 501098-65-3P 501098-73-3P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of benzothiazepine derivs. used as ileal bile acid transport inhibitors for treatment of hyperlipidemia)

RN 439086-76-7 CAPLUS

CN Benzeneacetic acid, α-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 439086-97-2 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -[[[(7-bromo-3-butyl-3-ethyl-2,3,4,5-tetrahydro-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl)oxy]acetyl]amino]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-13-5 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-18-0 CAPLUS

CN Glycine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439088-19-4 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-, methyl ester, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439088-54-7 CAPLUS

CN Glycine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 501098-36-8 CAPLUS

CN Benzeneacetamide,  $\alpha$ -[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-N-(2-hydroxyethyl)-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501098-65-3 CAPLUS


CN Carbamic acid, [[3-[[[(2R)-[[[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]methyl]phenyl]iminomethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 501098-73-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[(2R)-[[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 439088-52-5P 501098-38-0P 501098-40-4P  
 501098-41-5P 501098-42-6P 501098-43-7P  
 501098-44-8P 501098-45-9P 501098-46-0P  
 501098-47-1P 501098-48-2P 501098-49-3P  
 501098-50-6P 501098-51-7P 501098-52-8P  
 501098-53-9P 501098-54-0P 501098-56-2P  
 501098-57-3P 501098-58-4P 501098-59-5P  
 501098-60-8P 501098-61-9P 501098-62-0P  
 501098-63-1P 501098-64-2P 501098-66-4P  
 501098-67-5P 501098-68-6P 501098-69-7P  
 501098-70-0P 501098-71-1P 501098-72-2P  
 501098-74-4P 501098-76-6P 501098-77-7P  
 501098-78-8P 501098-79-9P 501098-81-3P  
 501098-83-5P 501098-84-6P 501098-85-7P


RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(preparation of benzothiazepine derivs. used as ileal bile acid transport inhibitors for treatment of hyperlipidemia)

RN 439088-52-5 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -[[[(7-bromo-3-butyl-3-ethyl-2,3,4,5-tetrahydro-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl)oxy]acetyl]amino]-, methyl ester, ( $\alpha$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501098-38-0 CAPLUS

CN Ethanaminium, 2-[[[(2R)-[[[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]-N,N,N-trimethyl-, acetate (9CI) (CA INDEX NAME)

CM 1

CRN 501098-37-9

CMF C37 H51 N4 O5 S2

CCN(C)CCNC(=O)[C@H](c1ccccc1)NC(=O)COc2cc(Sc)c3cc4c2S(=O)(=O)C(CC4)(CC)N(C3)c5ccccc5
$$\text{—O—}\overset{\text{O}}{\parallel}\text{C—CH}_3$$

CM 1

CRN 501098-39-1


CMF C34 H44 N4 O5 S2

CCNCC(=O)N[C@@H](Cc1ccccc1)C(=O)OCCOc2cc(Sc)c3cc(ccc3n2C(=O)OCC(C)(C)CCCC)c4ccccc4

Page 73


10/256,198

CRN 64-19-7  
CMF C2 H4 O2




RN 501098-41-5 CAPLUS  
CN Glycinamide, (2R)-N-[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501098-42-6 CAPLUS  
CN L-Serinamide, [[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-(2R)-2-phenylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501098-43-7 CAPLUS  
CN Benzeneacetamide, α-[[[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 501098-44-8 CAPLUS

CN Benzeneacetamide, α-[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]-, (αR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 501098-45-9 CAPLUS

CN Glycinamide, (2R)-N-[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-N-hydroxy-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 501098-46-0 CAPLUS

CN Glycinamide, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-N-(2,2,2-trifluoroethyl)-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501098-47-1 CAPLUS


CN D-Glucitol, 1-deoxy-1-[[ (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycylglycyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 501098-48-2 CAPLUS

CN Glycinamide, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-N-(2-fluoroethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 501098-49-3 CAPLUS

CN Glycinamide, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 501098-50-6 CAPLUS

CN Glycinamide, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-N-[(4-hydroxy-3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A


PAGE 1-B

—OH

RN 501098-51-7 CAPLUS

CN Glycinamide, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501098-52-8 CAPLUS

CN Glycinamide, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-N-[2-[4-(aminosulfonyl)phenyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




—NH<sub>2</sub>

RN 501098-53-9 CAPLUS

CN Glycinamide, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-N-[2-[[ (dimethylamino) sulfonyl] amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


—NMe<sub>2</sub>

RN 501098-54-0 CAPLUS


CN Glycinamide, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-N-[2-[[ (2-pyrimidinylamino) carbonyl] amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 501098-56-2 CAPLUS

CN D-Glucitol, 1-deoxy-1-[[ (2R)-[[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 501098-57-3 CAPLUS

CN D-Glucitol, 1-[[ (2R)-[[[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]-1-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 501098-58-4 CAPLUS

CN Benzeneacetamide, α-[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-N-[3-(4-morpholinyl)propyl]-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 501098-59-5 CAPLUS

CN Benzeneacetamide, α-[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-N-[2-(1H-imidazol-4-yl)ethyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501098-60-8 CAPLUS

CN Benzeneacetamide, α-[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-

yl]oxy]acetyl]amino]-N-[2-[[[(dimethylamino)sulfonyl]amino]ethyl]-,  
( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 501098-61-9 CAPLUS

CN Benzeneacetamide,  $\alpha$ -[[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-N-[2-(2-hydroxyphenoxy)ethyl]-, ( $\alpha$ R)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 501098-62-0 CAPLUS

CN Benzeneacetamide, N-[(3-aminophenyl)methyl]- $\alpha$ -[[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501098-63-1 CAPLUS

CN Benzeneacetamide,  $\alpha$ -[[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-

(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-N-[(3,4-dihydro-3-hydroxy-2H-1,5-benzodioxepin-3-yl)methyl]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501098-64-2 CAPLUS

CN Carbamic acid, [3-[[[(2R)-[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]methyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—OBu-t

RN 501098-66-4 CAPLUS

CN Benzeneacetamide,  $\alpha$ -[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-N-[2-(3,4-dihydroxyphenyl)-2-methoxyethyl]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 501098-67-5 CAPLUS

CN Benzeneacetamide, α-[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-N-(2,3-dihydroxypropyl)-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 501098-68-6 CAPLUS

CN Benzeneacetamide, α-[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






—Bu-n

RN 501098-69-7 CAPLUS

CN Benzeneacetamide,  $\alpha$ -[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-N-[2-(2,4-dioxo-3-thiazolidinyl)ethyl]-, ( $\alpha$ R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 501098-70-0 CAPLUS

CN Benzeneacetamide,  $\alpha$ -[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-N-[3-(4-methyl-1-piperazinyl)propyl]-, ( $\alpha$ R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 501098-71-1 CAPLUS

CN Benzeneacetamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]- $\alpha$ -[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-, ( $\alpha$ R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 501098-72-2 CAPLUS

CN Benzeneacetamide,  $\alpha$ -[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-N-[(2,3-dihydro-5,6-dimethoxy-2-benzofuranyl)methyl]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 501098-74-4 CAPLUS

CN Glycinamide, (2R)-N-[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-N-(4-nitrophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 501098-76-6 CAPLUS

CN Benzeneacetamide,  $\alpha$ -[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-N-[2-[(2-pyrimidinylamino)carbonyl]amino]ethyl]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 501098-77-7 CAPLUS

CN Benzeneacetamide,  $\alpha$ -[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-N-[2-[(2-pyridinylamino)carbonyl]amino]ethyl]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501098-78-8 CAPLUS

CN Benzeneacetamide, N-[2-[4-(aminocarbonyl)phenoxy]ethyl]- $\alpha$ -[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—NH<sub>2</sub>

RN 501098-79-9 CAPLUS

CN Benzeneacetamide,  $\alpha$ -[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-N-[2-(2-oxo-1-imidazolidinyl)ethyl]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 501098-81-3 CAPLUS

CN Benzeneacetamide, α-[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-N-(4-piperidinylmethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501098-83-5 CAPLUS


CN Benzeneacetamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-α-[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-, (αR)-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 501098-82-4.

CMF C40 H47 N5 O5 S2


Absolute stereochemistry.



CM 2

CRN 64-19-7


CMF C2 H4 O2



RN 501098-84-6 CAPLUS

CN D-Glucitol, 1-deoxy-1-[[ (2R)-[[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino] (4-hydroxyphenyl)acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 501098-85-7 CAPLUS

CN D-Glucitol, 1-deoxy-1-[[ (2R)-[[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]methylamino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 439086-77-8


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of benzothiazepine derivs. used as ileal bile acid transport inhibitors for treatment of hyperlipidemia)

RN 439086-77-8 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-4-hydroxy-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/256,198

L4 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:487544 CAPLUS

DOCUMENT NUMBER: 137:63270

TITLE: Preparation of N-[(8-benzothiazepinyloxy)acetyl]phenyl  
glycinates and analogs as ileal bile acid transport  
inhibitors

INVENTOR(S): Starke, Ingemar; Dahlstrom, Mikael; Blomberg, David

PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 161 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002050051	A1	20020627	WO 2001-GB5554	20011217
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2431461	AA	20020627	CA 2001-2431461	20011217
AU 2002022228	A5	20020701	AU 2002-22228	20011217
EP 1345918	A1	20030924	EP 2001-271366	20011217
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EE 200300307	A	20031015	EE 2003-307	20011217
BR 2001016397	A	20031111	BR 2001-16397	20011217
JP 2004516285	T2	20040603	JP 2002-551548	20011217
JP 3665055	B2	20050629		
NZ 526562	A	20050128	NZ 2001-526562	20011217
ZA 2003004266	A	20040830	ZA 2003-4266	20030530
BG 107928	A	20040831	BG 2003-107928	20030619
NO 2003002829	A	20030815	NO 2003-2829	20030620
US 2004067933	A1	20040408	US 2003-451262	20030620
JP 2004196815	A2	20040715	JP 2004-38960	20040216
PRIORITY APPLN. INFO.:			SE 2000-4811	A 20001221
			GB 2001-12592	A 20010524
			JP 2002-551548	A3 20011217
			WO 2001-GB5554	W 20011217

OTHER SOURCE(S): MARPAT 137:63270

GI





AB Title compds., e.g., I, were prepared as ileal bile acid transport inhibitors (no data).

IT 439086-76-7P 439086-77-8P 439086-78-9P  
 439086-79-0P 439086-80-3P 439086-81-4P  
 439086-82-5P 439086-83-6P 439086-84-7P  
 439086-85-8P 439086-86-9P 439086-87-0P  
 439086-88-1P 439086-89-2P 439086-90-5P  
 439086-91-6P 439086-92-7P 439086-93-8P  
 439086-94-9P 439086-95-0P 439086-96-1P  
 439086-97-2P 439086-98-3P 439086-99-4P  
 439087-00-0P 439087-01-1P 439087-02-2P  
 439087-03-3P 439087-04-4P 439087-05-5P  
 439087-06-6P 439087-07-7P 439087-08-8P  
 439087-09-9P 439087-10-2P 439087-11-3P  
 439087-12-4P 439087-13-5P 439087-14-6P  
 439087-15-7P 439087-16-8P 439087-17-9P  
 439087-18-0P 439087-19-1P 439087-20-4P  
 439087-21-5P 439087-22-6P 439087-23-7P  
 439087-24-8P 439087-25-9P 439087-26-0P  
 439087-27-1P 439087-28-2P 439087-29-3P  
 439087-30-6P 439087-31-7P 439087-32-8P  
 439087-33-9P 439087-34-0P 439087-35-1P  
 439087-36-2P 439087-37-3P 439087-38-4P  
 439087-39-5P 439087-41-9P 439087-43-1P  
 439087-45-3P 439087-47-5P 439087-48-6P  
 439087-49-7P 439087-50-0P 439087-51-1P  
 439087-52-2P 439087-53-3P 439087-54-4P  
 439087-55-5P 439087-56-6P 439087-57-7P  
 439087-58-8P 439087-59-9P 439087-60-2P  
 439087-61-3P 439087-62-4P 439087-63-5P  
 439087-64-6P 439087-65-7P 439087-66-8P  
 439087-67-9P 439087-68-0P 439087-69-1P  
 439087-70-4P 439087-71-5P 439087-72-6P  
 439087-73-7P 439087-74-8P 439087-75-9P  
 439087-76-0P 439087-77-1P 439087-78-2P  
 439087-79-3P 439087-80-6P 439087-81-7P  
 439087-82-8P 439087-83-9P 439087-84-0P  
 439087-85-1P 439087-86-2P 439087-87-3P  
 439087-88-4P 439087-89-5P 439087-91-9P  
 439087-92-0P 439087-93-1P 439087-94-2P  
 439087-95-3P 439087-96-4P 439087-97-5P  
 439087-98-6P 439087-99-7P 439088-00-3P  
 439088-01-4P 439088-02-5P 439088-03-6P  
 549501-80-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES


(Uses)

(preparation of N-[(8-benzothiazepinyloxy)acetyl]phenylglycinates and analogs as ileal bile acid transport inhibitors)

RN 439086-76-7 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 439086-77-8 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-4-hydroxy-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439086-78-9 CAPLUS

CN 2-Thiopheneacetic acid,  $\alpha$ -[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]- (9CI) (CA INDEX NAME)

RN 439086-79-0 CAPLUS


CN Benzeneacetic acid,  $\alpha$ -[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 439086-80-3 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-3-hydroxy-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439086-81-4 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-4-hydroxy-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439086-82-5 CAPLUS

CN D-Glutamic acid, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-

(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439086-83-6 CAPLUS

CN Glycine, N-[2-[[[(2R)-[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439086-84-7 CAPLUS

CN Glycine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycylglycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439086-85-8 CAPLUS

CN Benzeneacetic acid, α-[[2-[(7-bromo-3-butyl-3-ethyl-2,3,4,5-tetrahydro-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl)oxy]-1-oxopropyl]amino]-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439086-86-9 CAPLUS

CN Benzeneacetic acid, α-[[[(7-bromo-3-butyl-3-ethyl-2,3,4,5-tetrahydro-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl)oxy]phenylacetyl]amino]-, (αR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439086-87-0 CAPLUS

CN Benzeneacetic acid, α-[[[(3,3-dibutyl-2,3,4,5-tetrahydro-7-methoxy-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl)oxy]acetyl]amino]-, (αR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439086-88-1 CAPLUS

CN Glycine, (2R)-N-[[[(3,3-dibutyl-2,3,4,5-tetrahydro-7-methoxy-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl)oxy]acetyl]-2-phenylglycyl]- (9CI) (CA INDEX NAME)


10/256,198

Absolute stereochemistry.




RN 439086-89-2 CAPLUS

CN Benzeneacetic acid, α-[[[(3,3-dibutyl-2,3,4,5-tetrahydro-7-methoxy-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl)oxy]acetyl]amino]-2-fluoro- (9CI) (CA INDEX NAME)



RN 439086-90-5 CAPLUS


CN Benzeneacetic acid, α-[[[(3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl)oxy]acetyl]amino]-2-fluoro- (9CI) (CA INDEX NAME)



RN 439086-91-6 CAPLUS

CN Phosphonic acid, [(S)-[[[(7-bromo-3-butyl-3-ethyl-2,3,4,5-tetrahydro-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl)oxy]acetyl]amino]phenylmethyl]-, monoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439086-92-7 CAPLUS


CN Benzeneacetic acid,  $\alpha$ -[[[(7-bromo-3-butyl-3-ethyl-2,3,4,5-tetrahydro-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl)oxy]acetyl]amino]-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439086-93-8 CAPLUS


CN Benzeneacetic acid,  $\alpha$ -[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]- $\alpha$ -methyl- (9CI) (CA INDEX NAME)




RN 439086-94-9 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -[[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]methylamino]-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439086-95-0 CAPLUS

CN Benzenepropanoic acid,  $\beta$ -[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]- (9CI) (CA INDEX NAME)

RN 439086-96-1 CAPLUS


CN Benzeneacetic acid,  $\alpha$ -[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]methylamino]- (9CI) (CA INDEX NAME)

RN 439086-97-2 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 439086-98-3 CAPLUS

CN Ethanesulfonic acid, 2-[[[(2S)-[[[(7-bromo-3-butyl-3-ethyl-2,3,4,5-tetrahydro-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl)oxy]acetyl]amino]phenylacetyl]amino]-, monoammonium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● NH<sub>3</sub>

RN 439086-99-4 CAPLUS

CN Benzeneacetic acid, α-[[[(3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-methoxy-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl)oxy]acetyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439087-00-0 CAPLUS

CN Benzeneacetic acid, α-[[[(3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-

(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-01-1 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -[[[(7-bromo-3,3-dibutyl-2,3,4,5-tetrahydro-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl)oxy]acetyl]amino]-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-02-2 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -[[[(3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-methoxy-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl)oxy]acetyl]amino]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439087-03-3 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -[[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(1-methylethoxy)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-

yl]oxy]acetyl]amino]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-04-4 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylsulfonyl)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-05-5 CAPLUS


CN Benzeneacetic acid,  $\alpha$ -[[[7-bromo-3,3-dibutyl-2,3,4,5-tetrahydro-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439087-06-6 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -[[[7-bromo-3-butyl-3-ethyl-2,3,4,5-tetrahydro-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-2,3-dihydroxy- (9CI) (CA INDEX NAME)




RN 439087-07-7 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -[[[(3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-methoxy-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl)oxy]acetyl]amino]-2,3-dihydroxy- (9CI) (CA INDEX NAME)



RN 439087-08-8 CAPLUS


CN Benzeneacetic acid,  $\alpha$ -[[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-2,3-dihydroxy- (9CI) (CA INDEX NAME)



RN 439087-09-9 CAPLUS


CN Benzeneacetic acid,  $\alpha$ -[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-4-fluoro-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439087-10-2 CAPLUS


CN 1H-Indole-3-acetic acid, α-[[[(3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]- (9CI) (CA INDEX NAME)



RN 439087-11-3 CAPLUS


CN Benzeneacetic acid, α-[[[(3,3-dibutyl-2,3,4,5-tetrahydro-7-methoxy-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl)oxy]acetyl]amino]-4-fluoro-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439087-12-4 CAPLUS


CN 1H-Indole-3-acetic acid, α-[[[(3,3-dibutyl-2,3,4,5-tetrahydro-7-methoxy-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl)oxy]acetyl]amino]- (9CI) (CA INDEX NAME)



RN 439087-13-5 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-14-6 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -[[[3-butyl-3-ethyl-7-(ethylthio)-2,3,4,5-tetrahydro-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-15-7 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-[(2-hydroxyethyl)thio]-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-16-8 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -[[[3-butyl-7-[[2-(dimethylamino)ethyl]thio]-3-ethyl-2,3,4,5-tetrahydro-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-17-9 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-[(1-methylethyl)thio]-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-18-0 CAPLUS

CN Glycine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-19-1 CAPLUS

CN Glycine, (2R)-N-[[[(7-bromo-3-butyl-3-ethyl-2,3,4,5-tetrahydro-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl)oxy]acetyl]-2-phenylglycyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-20-4 CAPLUS

CN D-Serine, (2R)-N-[[[(3,3-dibutyl-2,3,4,5-tetrahydro-7-methoxy-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl)oxy]acetyl]-2-phenylglycyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439087-21-5 CAPLUS

CN Glycine, (2R)-N-[[[(3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl)oxy]acetyl]-2-(4-hydroxyphenyl)glycyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 439087-22-6 CAPLUS

CN Lysine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-23-7 CAPLUS

CN D-Tyrosine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439087-24-8 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -[[[5-(4-aminophenyl)-3,3-dibutyl-2,3,4,5-tetrahydro-1,1-dioxido-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-,

10/256,198

(αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-25-9 CAPLUS

CN Ethanesulfonic acid, 2-[[[(2R)-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]-, monoammonium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● NH<sub>3</sub>

RN 439087-26-0 CAPLUS

CN Ethanesulfonic acid, 2-[[[(2R)-[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]-, monoammonium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● NH<sub>3</sub>

RN 439087-27-1 CAPLUS

CN Glycine, (2R)-N-[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 439087-28-2 CAPLUS

CN Glycine, (2R)-N-[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439087-29-3 CAPLUS

CN Benzeneacetic acid, α-[[[2-[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]-1-

oxopropyl]amino]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-30-6 CAPLUS

CN Benzenecetic acid,  $\alpha$ -[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]phenylacetyl]amino]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-31-7 CAPLUS

CN Ethanesulfonic acid, 2-[[[(2R)-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino](4-hydroxyphenyl)acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-32-8 CAPLUS

CN Ethanesulfonic acid, 2-[[[(2R)-[[[(3R)-3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino](4-hydroxyphenyl)acetyl]amino]-, monoammonium salt (9CI) (CA INDEX NAME)


Absolute stereochemistry.

● NH<sub>3</sub>

RN 439087-33-9 CAPLUS

CN Ethanesulfonic acid, 2-[[[(2R)-[[[(3S)-3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino](4-hydroxyphenyl)acetyl]amino]-, monoammonium salt (9CI) (CA INDEX NAME)


Absolute stereochemistry.

● NH<sub>3</sub>

RN 439087-34-0 CAPLUS

CN β-Alanine, (2R)-N-[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-35-1 CAPLUS

CN Butanoic acid, 4-[[[(2R)-[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-36-2 CAPLUS

CN  $\beta$ -Alanine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-37-3 CAPLUS

CN Hexanoic acid, 6-[[[(2R)-[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-38-4 CAPLUS

CN β-Alanine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-39-5 CAPLUS

CN Benzeneacetic acid, α-[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-4-methoxy-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-41-9 CAPLUS

CN Ethanesulfonic acid, 2-[[[(2R)-2-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-1-oxo-2-phenylpropyl]amino]-, monoammonium salt (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● NH<sub>3</sub>

RN 439087-43-1 CAPLUS  
 CN Ethanesulfonic acid, 2-[[[(2R)-[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]methylamino]-, monoammonium salt (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




● NH<sub>3</sub>

RN 439087-45-3 CAPLUS  
 CN Ethanesulfonic acid, 2-[[[(2S)-[[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]-, monoammonium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.






● NH<sub>3</sub>


RN 439087-47-5 CAPLUS

CN Glycine, N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylalanyl- (9CI) (CA INDEX NAME)



RN 439087-48-6 CAPLUS

CN Ethanesulfonic acid, 2-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino] (2-fluorophenyl)acetyl]amino]- (9CI) (CA INDEX NAME)




RN 439087-49-7 CAPLUS

CN Glycine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycylglycyl- (2R)-2-phenylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—CO<sub>2</sub>H

RN 439087-50-0 CAPLUS

CN Benzeneacetic acid, α-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-4-hydroxy-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-51-1 CAPLUS

CN Ethanesulfonic acid, 2-[[[(2S)-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino](4-hydroxyphenyl)acetyl]amino]-, monoammonium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● NH<sub>3</sub>

RN 439087-52-2 CAPLUS

CN D-Histidine, (2R)-N-[[[(3R)-3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-53-3 CAPLUS

CN D-Histidine, (2R)-N-[[[(3S)-3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439087-54-4 CAPLUS

CN Glycine, (2R)-N-[[[3,3-dibutyl-5-[4-(1,1-dimethylethyl)phenyl]-2,3,4,5-

tetrahydro-7-(methylthio)-1,1-dioxido-1,5-benzothiazepin-8-yl]oxy]acetyl]-  
2-phenylglycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-55-5 CAPLUS


CN Benzeneacetic acid,  $\alpha$ -[[[(3-butyl-3-ethyl-2,3,4,5-tetrahydro-8-methoxy-1,1-dioxido-5-phenyl-1,5-benzothiazepin-7-yl)thio]acetyl]amino]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439087-56-6 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -[[[[3-butyl-7-[(carboxymethyl)thio]-3-ethyl-2,3,4,5-tetrahydro-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]- (9CI) (CA INDEX NAME)




RN 439087-57-7 CAPLUS

CN D-Serine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycylglycyl-

(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-58-8 CAPLUS

CN L-Serine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycylglycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-59-9 CAPLUS

CN Glycine, (2R)-N-[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-2-carboxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-60-2 CAPLUS

CN L-Serine, (2R)-N-[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-61-3 CAPLUS

CN D-Serine, (2R)-N-[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 439087-62-4 CAPLUS

CN L-Serine, (2S)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 439087-63-5 CAPLUS

CN D-Serine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 439087-64-6 CAPLUS

CN L-Serine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-L-seryl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-65-7 CAPLUS

CN D-Serine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-L-seryl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-66-8 CAPLUS

CN Serine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-67-9 CAPLUS

CN Benzeneacetic acid, α-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-68-0 CAPLUS

CN Glycine, (2S)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439087-69-1 CAPLUS

CN Ethanesulfonic acid, 2-[[[(2S)-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]-, monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.






● Na

RN 439087-70-4 CAPLUS

CN Glycinamide, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-N-(2-sulfoethyl)-, monoammonium salt (9CI) (CA INDEX NAME)


Absolute stereochemistry.

● NH<sub>3</sub>

RN 439087-71-5 CAPLUS

CN Glycine, (2S)-N-[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-1,1-dioxido-5-phenyl-1,5-benzothiazepin-7-yl]oxy]acetyl]-2-phenylglycyl-, monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Na

RN 439087-72-6 CAPLUS

CN Glycine, (2R)-N-[[[(3R)-3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-73-7 CAPLUS

CN Glycine, (2R)-N-[[[(3S)-3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439087-74-8 CAPLUS

CN Phosphinic acid, [2-[[[(2R)-[[[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]ethyl]methyl-, ethyl ester (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 439087-75-9 CAPLUS

CN Phosphonic acid, [[[(2R)-[[[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]methyl]-, diethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-76-0 CAPLUS

CN Phosphonic acid, [[[(2R)-[[[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]methyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439087-77-1 CAPLUS

CN Phosphonic acid, [2-[[[(2R)-[[[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-

(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]ethyl]methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-78-2 CAPLUS

CN Phosphonic acid, [[[ (2R)-[[[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-79-3 CAPLUS

CN Phosphonic acid, [[[ (2R)-[[[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]methyl]methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-80-6 CAPLUS

CN Phosphonic acid, [2-[[[(2R)-[[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]ethyl]methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-81-7 CAPLUS

CN Phosphonic acid, [[[(2R)-[[[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]methyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-82-8 CAPLUS

CN Phosphonic acid, [[[(2R)-[[[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-83-9 CAPLUS

CN Benzeneacetamide,  $\alpha$ -[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-N-[2-(ethylmethylphosphinyl)ethyl]-, ( $\alpha$ R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-84-0 CAPLUS

CN Cysteine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-85-1 CAPLUS

CN D-Cysteine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-86-2 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -[[3-[(7-bromo-3-butyl-3-ethyl-2,3,4,5-tetrahydro-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl)oxy]-1-oxopropyl]amino]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-87-3 CAPLUS

CN L-Cysteine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-S-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-88-4 CAPLUS

CN Benzeneacetamide,  $\alpha$ -[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-N-[2-(ethylmethylphosphinyl)ethyl]-4-hydroxy-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-89-5 CAPLUS

CN Phosphinic acid, [2-[[[(2R)-[[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino] (4-hydroxyphenyl)acetyl]amino]ethyl]methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-91-9 CAPLUS

CN  $\beta$ -Alanine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-2-[(methylthio)methyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439087-92-0 CAPLUS

CN D-Cysteine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-S-methyl- (9CI) (CA INDEX NAME)




Absolute stereochemistry.



RN 439087-93-1 CAPLUS

CN Glycine, (2R)-N-[[[3,3-dibutyl-5-(4-chlorophenyl)-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-94-2 CAPLUS

CN Ethanesulfonic acid, 2-[[[(2R)-(4-hydroxyphenyl)]][[[2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-3,3-dipropyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]acetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439087-95-3 CAPLUS

CN Glycine, (2R)-2-(4-hydroxyphenyl)-N-[[[2,3,4,5-tetrahydro-7-(methylthio)-

1,1-dioxido-5-phenyl-3,3-dipropyl-1,5-benzothiazepin-8-yl]oxy]acetyl]glycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-96-4 CAPLUS

CN Ethanesulfonic acid, 2-[[[(2R)-[[[(3,3-dibutyl-2,3,4,5-tetrahydro-7-methoxy-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl)oxy]acetyl]amino](4-hydroxyphenyl)acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-97-5 CAPLUS

CN Ethanesulfonic acid, 2-[[[(2R)-[[[(3-butyl-3-ethyl-2,3,4,5-tetrahydro-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl)oxy]acetyl]amino](4-hydroxyphenyl)acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-98-6 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -[[[3,3-dibutyl-5-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-2,3,4,5-tetrahydro-1,1-dioxido-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439087-99-7 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -[[[3,3-dibutyl-5-[4-[[[(1,1-dimethylethyl)amino]carbonyl]amino]phenyl]-2,3,4,5-tetrahydro-1,1-dioxido-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439088-00-3 CAPLUS

CN Ethanesulfonic acid, 2-[[[(2R)-[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439088-01-4 CAPLUS

CN Ethanesulfonic acid, 2-[[[(2R)-[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino](4-hydroxyphenyl)acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439088-02-5 CAPLUS


CN D-Serine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-D-seryl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439088-03-6 CAPLUS


CN Phosphinic acid, [[[[[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]methyl]methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 549501-80-6 CAPLUS

CN L-Alanine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-3-(methylsulfinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 439088-19-4P 439088-20-7P 439088-21-8P  
 439088-22-9P 439088-23-0P 439088-24-1P  
 439088-25-2P 439088-26-3P 439088-27-4P  
 439088-28-5P 439088-29-6P 439088-30-9P  
 439088-31-0P 439088-32-1P 439088-33-2P  
 439088-34-3P 439088-36-5P 439088-37-6P  
 439088-38-7P 439088-39-8P 439088-40-1P  
 439088-41-2P 439088-42-3P 439088-43-4P  
 439088-44-5P 439088-45-6P 439088-46-7P  
 439088-47-8P 439088-48-9P 439088-49-0P  
 439088-50-3P 439088-51-4P 439088-52-5P  
 439088-53-6P 439088-54-7P 439088-55-8P  
 439088-56-9P 439088-57-0P 439088-58-1P  
 439088-59-2P 439088-60-5P 439088-61-6P  
 439088-63-8P 439088-65-0P 439088-66-1P  
 439088-75-2P 439088-76-3P 439088-78-5P  
 439088-79-6P 439088-80-9P 439088-81-0P  
 439088-82-1P 439088-90-1P 439089-04-0P  
 439089-06-2P 439089-08-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of N-[(8-benzothiazepinyloxy)acetyl]phenylglycinates and analogs as ileal bile acid transport inhibitors)

RN 439088-19-4 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-, methyl ester, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439088-20-7 CAPLUS


CN Benzeneacetic acid,  $\alpha$ -[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-4-hydroxy-, methyl ester, ( $\alpha$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439088-21-8 CAPLUS

CN 2-Thiopheneacetic acid,  $\alpha$ -[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 439088-22-9 CAPLUS


CN Benzeneacetic acid,  $\alpha$ -[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-4-(trifluoromethyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 439088-23-0 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -[[2-[(7-bromo-3-butyl-3-ethyl-2,3,4,5-tetrahydro-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl)oxy]-1-oxopropyl]amino]-, methyl ester, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439088-24-1 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -[[[[(7-bromo-3-butyl-3-ethyl-2,3,4,5-tetrahydro-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl)oxy]phenylacetyl]amino]-, methyl ester, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439088-25-2 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -[[[[(3,3-dibutyl-2,3,4,5-tetrahydro-7-methoxy-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl)oxy]acetyl]amino]-, methyl ester, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439088-26-3 CAPLUS


CN Glycine, (2R)-N-[[[(3,3-dibutyl-2,3,4,5-tetrahydro-7-methoxy-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl)oxy]acetyl]-2-phenylglycyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439088-27-4 CAPLUS


CN Benzeneacetic acid,  $\alpha$ -[[[(3,3-dibutyl-2,3,4,5-tetrahydro-7-methoxy-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl)oxy]acetyl]amino]-2-fluoro-, methyl ester (9CI) (CA INDEX NAME)



RN 439088-28-5 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -[[[(3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl)oxy]acetyl]amino]-2-fluoro-, methyl ester (9CI) (CA INDEX NAME)






RN 439088-29-6 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -[[[(7-bromo-3,3-dibutyl-2,3,4,5-tetrahydro-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl)oxy]acetyl]amino]-3-hydroxy-, methyl ester, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439088-30-9 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -[[[(7-bromo-3,3-dibutyl-2,3,4,5-tetrahydro-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl)oxy]acetyl]amino]-4-hydroxy-, methyl ester, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439088-31-0 CAPLUS

CN D-Serine, (2R)-N-[[[(3,3-dibutyl-2,3,4,5-tetrahydro-7-methoxy-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl)oxy]acetyl]-2-phenylglycyl-O-(1,1-dimethylethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439088-32-1 CAPLUS


CN Glycine, N-[2-[[[(2R)-[[[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439088-33-2 CAPLUS

CN Benzeneacetic acid, α-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-α-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 439088-34-3 CAPLUS


CN Glycine, N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylalanyl-, methyl ester (9CI) (CA INDEX NAME)



RN 439088-36-5 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -[[[3,3-dibutyl-5-[4-[[1,1-dimethylethoxy)carbonyl]amino]phenyl]-2,3,4,5-tetrahydro-1,1-dioxido-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-, methyl ester, ( $\alpha$ R)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 439088-37-6 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -[[[7-bromo-3-butyl-3-ethyl-2,3,4,5-tetrahydro-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-, methyl ester, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439088-38-7 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-methoxy-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-, methyl ester, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439088-39-8 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-, methyl ester, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439088-40-1 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-, methyl ester, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439088-41-2 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-, methyl ester, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439088-42-3 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(1-methylethoxy)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-, methyl ester, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439088-43-4 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylsulfonyl)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-, methyl ester, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439088-44-5 CAPLUS


CN Benzeneacetic acid,  $\alpha$ -[[[(7-bromo-3,3-dibutyl-2,3,4,5-tetrahydro-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl)oxy]acetyl]amino]-, methyl ester, ( $\alpha$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439088-45-6 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -[[[(7-bromo-3-butyl-3-ethyl-2,3,4,5-tetrahydro-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl)oxy]acetyl]amino]-2,3-dihydroxy-, methyl ester (9CI) (CA INDEX NAME)




RN 439088-46-7 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -[[[(3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-methoxy-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl)oxy]acetyl]amino]-2,3-dihydroxy-, methyl ester (9CI) (CA INDEX NAME)



RN 439088-47-8 CAPLUS


CN Benzeneacetic acid,  $\alpha$ -[[[(3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl)oxy]acetyl]amino]-2,3-dihydroxy-, methyl ester (9CI) (CA INDEX NAME)



RN 439088-48-9 CAPLUS


CN Benzeneacetic acid, α-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-4-fluoro-, methyl ester, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439088-49-0 CAPLUS


CN 1H-Indole-3-acetic acid, α-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 439088-50-3 CAPLUS


CN Benzeneacetic acid, α-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-methoxy-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-4-fluoro-, methyl ester, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439088-51-4 CAPLUS


CN 1H-Indole-3-acetic acid,  $\alpha$ -[[[(3,3-dibutyl-2,3,4,5-tetrahydro-7-methoxy-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl)oxy]acetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 439088-52-5 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -[[[(7-bromo-3-butyl-3-ethyl-2,3,4,5-tetrahydro-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl)oxy]acetyl]amino]-, methyl ester, ( $\alpha$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439088-53-6 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -[[[(3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl)oxy]acetyl]methylamino]-, methyl ester, ( $\alpha$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 439088-54-7 CAPLUS

CN Glycine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439088-55-8 CAPLUS

CN Glycine, (2R)-N-[[[7-bromo-3-butyl-3-ethyl-2,3,4,5-tetrahydro-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-N-methyl-2-phenylglycyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439088-56-9 CAPLUS

CN Glycine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439088-57-0 CAPLUS

CN Lysine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl-N6-[(1,1-dimethylethoxy)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439088-58-1 CAPLUS

CN D-Glutamic acid, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-, dimethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439088-59-2 CAPLUS

CN D-Tyrosine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439088-60-5 CAPLUS

CN Glycine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycylglycyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439088-61-6 CAPLUS

CN Phosphonic acid, [(S)-[[[(7-bromo-3-butyl-3-ethyl-2,3,4,5-tetrahydro-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl)oxy]acetyl]amino]phenylmethyl]-, diethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439088-63-8 CAPLUS

CN Glycine, (2R)-N-[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439088-65-0 CAPLUS


CN Benzeneacetic acid,  $\alpha$ -[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-4-hydroxy-, 1,1-dimethylethyl ester, ( $\alpha$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439088-66-1 CAPLUS


CN Benzeneacetic acid,  $\alpha$ -[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]methylamino]-, methyl ester (9CI) (CA INDEX NAME)



RN 439088-75-2 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-, methyl ester, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439088-76-3 CAPLUS

CN Glycine, (2S)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439088-78-5 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -[[3-[(7-bromo-3-butyl-3-ethyl-2,3,4,5-tetrahydro-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl)oxy]-1-oxopropyl]amino]-, 1,1-dimethylethyl ester, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439088-79-6 CAPLUS

CN L-Cysteine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-S-(triphenylmethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439088-80-9 CAPLUS

CN L-Cysteine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-S-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439088-81-0 CAPLUS

CN D-Cysteine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-S-(triphenylmethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439088-82-1 CAPLUS

CN L-Methionine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439088-90-1 CAPLUS

CN Glycine, (2R)-N-[[[3,3-dibutyl-5-(4-chlorophenyl)-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439089-04-0 CAPLUS

CN Benzeneacetic acid,  $\alpha$ -[[[5-(4-aminophenyl)-3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-, methyl ester, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439089-06-2 CAPLUS


CN Benzenecetic acid,  $\alpha$ -[[[3,3-dibutyl-5-[4-[[[(1,1-dimethylethyl)amino]carbonyl]amino]phenyl]-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-, methyl ester, ( $\alpha$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439089-08-4 CAPLUS

CN Benzenepropanoic acid,  $\beta$ -[[[3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



L4 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:676757 CAPLUS

DOCUMENT NUMBER: 135:210745

TITLE: Preparation of 1,5-benzothiazepines for use as hypolipidemics

INVENTOR(S): Starke, Ingemar; Dahlstrom, Michael; Blomberg, David

PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited

SOURCE: PCT Int. Appl., 72 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001066533	A1	20010913	WO 2001-GB909	20010305
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2401055	AA	20010913	CA 2001-2401055	20010305
EP 1263747	A1	20021211	EP 2001-909970	20010305
EP 1263747	B1	20041124		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001009011	A	20030603	BR 2001-9011	20010305
JP 2003525933	T2	20030902	JP 2001-565349	20010305
NZ 520951	A	20040528	NZ 2001-520951	20010305
AT 283266	E	20041215	AT 2001-909970	20010305
ZA 2002006739	A	20031124	ZA 2002-6739	20020822
NO 2002004217	A	20021009	NO 2002-4217	20020904
US 2003166927	A1	20030904	US 2002-220877	20020906
US 6906058	B2	20050614		
PRIORITY APPLN. INFO.:			SE 2000-772	A 20000308
			WO 2001-GB909	W 20010305
OTHER SOURCE(S):		MARPAT 135:210745		
GI				



AB Benzothiazepines I [R1, R2 = alkyl; one of R4 and R5 is R7(CR8R9)mNR10CO(CHR11)nO; R3, R6 and the other of R4 and R5 are H, halo,


nitro, cyano, hydroxy, amino, carboxy, mercapto, (un)substituted carbamoyl, sulfamoyl, alkyl, alkenyl, alkynyl, alkoxy, alkanoyl, etc.; R7 = carboxy, sulfo, sulfinio, phosphono, P(O)(ORa)(ORb), P(O)(OH)(ORa) (Ra, Rb = alkyl) or substituted carbamoyl; R8, R9 = H, alkyl, a saturated cyclic group or R8R9 = (un)substituted alkylene; R10 = H, (un)substituted alkyl; R11 = H, (un)substituted alkyl, carbocyclyl or heterocyclyl; m, n = 1-3] or their pharmaceutically acceptable salts, solvates, solvates and prodrugs were prepared for use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidemia. Thus, 3-butyl-3-ethyl-5-phenyl-7-[N-(carboxymethyl)carbamoyl]methoxy]-2,3,4,5-tetrahydro-1,5-benzothiazepine 1,1-dioxide was prepared from 3-butyl-3-ethyl-5-phenyl-7-hydroxy-2,3,4,5-tetrahydro-1,5-benzothiazepine 1,1-dioxide by treatment with Et bromoacetate, saponification, coupling with glycine tert-Bu ester, and ester cleavage using TFA.

IT 358375-25-4P 358375-47-0P 358375-48-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of benzothiazepines as hypolipidemics)

RN 358375-25-4 CAPLUS


CN Glycine, N-[[[(7-bromo-3-butyl-3-ethyl-2,3,4,5-tetrahydro-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl)oxy]acetyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 358375-47-0 CAPLUS

CN Cyclohexaneacetic acid,  $\alpha$ -[[[(3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl)oxy]acetyl]amino]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 358375-48-1 CAPLUS

CN Cyclohexaneacetic acid,  $\alpha$ -[[[(3,3-dibutyl-2,3,4,5-tetrahydro-7-methoxy-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl)oxy]acetyl]amino]-,

(αR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 358375-62-9P 358375-90-3P 358375-91-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of benzothiazepines as hypolipidemics)

RN 358375-62-9 CAPLUS


CN Glycine, N-[[[7-bromo-3-butyl-3-ethyl-2,3,4,5-tetrahydro-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-N-(phenylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 358375-90-3 CAPLUS

CN Cyclohexaneacetic acid, α-[[[[(3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]amino]-, methyl ester, (αR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 358375-91-4 CAPLUS

CN Cyclohexaneacetic acid, α-[[[[(3,3-dibutyl-2,3,4,5-tetrahydro-7-

10/256,198

methoxy-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl)oxy]acetyl]amino]-, methyl ester, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



## chain nodes :

18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39  
40 41 42 43 44 45 46 47 48 62

## ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

## chain bonds :

1-15 4-18 4-19 6-20 21-22 22-23 23-24 23-47 24-25 25-26 27-28 28-29 29-30  
30-31 30-45 31-32 33-34 34-35 35-36 36-37 36-46 37-38 39-40 40-41 41-42 42-43  
42-48 43-44

## ring bonds :

1-2 1-7 2-3 2-8 3-4 3-11 4-5 5-6 6-7 8-9 9-10 10-11 12-13 12-17 13-14  
14-15 15-16 16-17

## exact/norm bonds :

1-2 1-7 1-15 2-3 2-8 3-4 3-11 4-5 4-18 4-19 5-6 6-7 6-20 8-9 9-10 10-11  
21-22 23-24 23-47 24-25 25-26 27-28 28-29 29-30 30-45 31-32 33-34 34-35 35-36  
36-46 37-38 39-40 40-41 41-42 42-48

## exact bonds :

22-23 30-31 36-37 42-43 43-44

## normalized bonds :

12-13 12-17 13-14 14-15 15-16 16-17

G1: [\*1], [\*2], [\*3], [\*4]

## Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom  
12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS 20:CLASS  
21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:Atom 27:Atom 28:CLASS 29:CLASS  
30:CLASS 31:CLASS 32:CLASS 33:Atom 34:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS  
39:Atom 40:CLASS 41:CLASS 42:CLASS 43:CLASS 44:CLASS 45:CLASS 46:CLASS 47:CLASS  
48:CLASS 62:CLASS 63:CLASS